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Abstract: 
The Genomic Medicine Model aims to facilitate patient engagement, patient/provider education 
of genomics/personalized medicine, and uptake of risk-stratified evidence-based prevention 
guidelines using MeTree, a patient-facing family health history (FHH) collection and clinical 
decision support (CDS) program. Here we report the number of increased risk (above 
population-level risk) patients identified for breast/ovarian cancer, colon cancer, hereditary 
syndrome risk, and thrombosis; the prevalence of FHH elements triggering increased-risk status; 
and the resources needed to manage their risk. Study design: hybrid implementation-
effectiveness study of adults with upcoming well-visits in 2 primary care practices in 
Greensboro, NC. Participants: 1,184, mean age = 58.8, female = 58% (N = 694), non-
white = 20% (N = 215). Increased Risk: 44% (N = 523). Recommendations: genetic 
counseling = 26% (N = 308), breast MRI = 0.8% (N = 10), breast chemoprophylaxis = 5% 
(N = 58), early/frequent colonoscopies = 19% (N = 221), ovarian cancer screening referral = 1% 
(N = 14), thrombosis testing/counseling = 2.4% (N = 71). FHH elements: 8 FHH elements lead to 
37.3% of the increased risk categorizations (by frequency): first-degree-relative (FDR) with 
polyps age ≥60 (7.1%, N = 85), three relatives with Lynch-related cancers (5.4%, N = 65), FDR 
with polyps age <60 (5.1%, N = 61), three relatives on same side of family with same cancer 
(4.9%, N = 59), Gail score ≥1.66% (4.9%, N = 58), two relatives with breast cancer (one ≤age 
50) (4.1%, N = 49), one relative with breast cancer ≤age 40 (4.1%, N = 48), FDR with colon 
cancer age ≥60 (1.7%, N = 20). MeTree identifies a high percentage of individuals in the general 
primary care population needing non-routine risk management/prevention for the selected 
conditions. Implementing risk-stratification in primary care will likely increase demand for 
related-resources, particularly colon screening and GC. Understanding the prevalence of FHH 
elements helps predict resource needs and may aid in guideline development. 
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Article: 
INTRODUCTION 
Primary care providers (PCPs) remain on the periphery of genomic medicine despite the fact that 
some of these advances are highly applicable to primary care. Reasons for this wait and see 
attitude include the relative dearth of clinical utility evidence; limited genomics knowledge; and 
slow diffusion of research into practice [Watson et al., 1999]. An excellent example of this is 
family health history (FHH) based-risk stratification (one component of genomic medicine), 
which is widely accepted by PCPs but is rarely practiced [Acheson et al.,2000; Gramling et 
al., 2004]. 
Integration of genomic medicine into primary care may be facilitated by starting with a model 
based upon a widely accepted clinical concept with genomic medicine applicability and building 
upon it. The Genomedical Connection, a collaboration among Duke University, University of 
North Carolina at Greensboro, and Cone Health adopted this approach when developing the 
Genomic Medicine Model for primary care (GMM), which uses FHH as a foundation for 
bringing personalized/genomic medicine into primary care practices. Its goals include 
encouraging patients to become active partners in their healthcare, promoting education of 
patients and providers, and improving adherence to risk-stratified preventive care guidelines 
[Orlando et al., 2013b]. The core of the GMM is a patient-facing web-based FHH collection and 
clinical decision support (CDS) program, MeTree, and a series of educational materials designed 
to meet the needs of each stakeholder. 
The core of the GMM is a patient-facing web-based FHH collection and clinical decision support 
(CDS) program, MeTree, and a series of educational materials designed to meet the needs of 
each stakeholder. 
The initial CDS conditions (breast/ovarian cancer, colon cancer, hereditary cancer syndromes, 
and thrombosis) were chosen for the strength of the evidence linking FHH to risk level, clinical 
relevance, and level of acceptance by PCPs. Potential options for building upon the GMM's FHH 
core include expanding CDS conditions, adding context appropriate pharmacogenomic or 
genetic testing recommendations and, where the evidence supports it, incorporating genomic risk 
and/or diagnostic testing. 
When evaluating models designed to overcome barriers in clinical practice, like the GMM, it is 
important to assess implementation and effectiveness outcomes. To this end we have published 
papers describing the GMM's implementation, MeTree's development and assessment, and its 
successful uptake and acceptance by patients and providers [Orlando et al., 2013a, 2013b; Wu et 
al., 2013]. In this paper we described the impact of the GMM on one component of 
effectiveness: identification of patients at increased risk and the resources needed to manage 
their risk. 
METHODS 
Study Design and Setting 
The GMM was implemented in two community-based primary care practices at Cone Health 
(Greensboro, NC) as part of a real-world hybrid implementation-effectiveness study that 
collected data on implementation (i.e., user experience, work flow, uptake, etc.) as well as 
effectiveness [Curran et al., 2012] from October 15, 2009 to April 14, 2012. All adult patients 
with upcoming well-visit appointments were invited to participate. Exclusion criteria were: being 
adopted and not speaking English. On the day of their appointment participants came 1 hr early, 
completed MeTree, and received a copy of 1) their pedigree and 2) a patient report describing 
their risk for CDS conditions and with talking points for their appointment with their physician. 
Provider documents (pedigree, tabular-format FHH, and provider report detailing risk level and 
appropriate recommendations for risk management and preventive care) were attached to the 
patient's chart prior to the appointment. The full study protocol has been published [Orlando et 
al., 2011]. 
MeTree 
MeTree is a web-based software program that collects FHH and personal history from patients, 
calculates risk, and generates risk-stratified, evidence-based risk-management/prevention 
recommendations for PCPs. It collects FHH on 48 conditions and enough personal information 
to calculate the Gail Model and BRCAPRO breast cancer risk scores [Gail et al., 1989; Berry et 
al., 2002]. Decision support is provided for breast/ovarian cancer, colon cancer, hereditary 
cancer syndrome risk, and thrombosis. A list of possible recommendations for those at increased 
risk (i.e., non-routine recommendations) and the evidence supporting them are listed in Table I. 
Emphasis was placed upon the United States Preventive Services Task Force guidelines with 
which PCPs were most comfortable. For more details, see the published development and 
assessment paper [Orlando et al., 2013a]. 
Table I. MeTree's Non-Routine Recommendation Options for its Clinical Decision Support 
Conditions 
Condition Physician report action item 
Thrombosis Genetic testing for inherited thrombophilia [Buller et al., 2004] 
  Genetic counseling for comprehensive inherited thrombophilia risk assessment and 
management [Buller et al., 2004] 
Breast cancer Breast cancer surveillance via annual breast MRI and mammography [Berry et 
al., 2002; Saslow et al., 2007] 
  Discuss chemoprevention for breast cancer (tamoxifen or raloxifene) [Fisher et 
al., 1998; Vogel et al., 2006] 
  Discuss chemoprevention for breast cancer (tamoxifen) [Fisher et al., 1998] 
Ovarian cancer Refer to gynecologist for discussion of pros and cons of ovarian cancer screening via 
annual concurrent transvaginal ultrasound (TVUS) and CA-125 testing [Hampel et 
al., 2004] 
Colorectal cancer Early colorectal cancer surveillance (beginning at age 40) [Levin et al., 2008] 
  Early and more frequent colonoscopies (every 5 years beginning at age 40 or 10 years 
younger than the earliest diagnosis in the family, whichever comes first) [Levin et 
al., 2008] 
Hereditary 
cancer syndrome 
Genetic counseling for comprehensive cancer risk assessment and management 
[Vasen et al., 1999; Hampel et al.,2004; U.S. Preventive Services Task Force, 2005; 
Berliner et al., 2007; Levin et al., 2008] 
  Cancer risk management for Hereditary Breast and Ovarian Cancer syndrome, 
according to NCCN guidelines [National Comprehensive Cancer Network, 2011] 
  Cancer risk management for Hereditary Nonpolyposis Colorectal Cancer (aka, 
Lynch) syndrome, according to NCCN guidelines [National Comprehensive Cancer 
Network, 2011] 
  Cancer risk management for familial adenomatous polyposis, according to NCCN 
guidelines [National Comprehensive Cancer Network, 2011] 
  Cancer risk management for Li–Fraumeni syndrome, according to NCCN guidelines 
[National Comprehensive Cancer Network, 2011] 
  Cancer risk management for Cowden syndrome, according to NCCN guidelines 
[National Comprehensive Cancer Network, 2011] 
  Cancer risk management for hereditary cancer syndrome, according to published 
guidelines [National Comprehensive Cancer Network, 2011] 
Note that the italicized physician report action items are those that belong to the “Hereditary Risk” group 
of recommendations and those that are not italicized belong to the “Familial Risk” group of 
recommendations. 
 
Statistical Analysis 
All data entered into MeTree, and results of risk calculations and CDS recommendations were 
stored on a secure SQL relational database and analyzed using R statistical software [R Core 
Team, 2013]. 
Although MeTree has been assessed for clinical accuracy through by having a genetic 
counselor's review every pedigree and recommendation report, we wanted to further assess the 
analytic validity of MeTree for the guidelines it was intended to implement. To do this we coded 
all FHH risk factors leading to a non-routine recommendation (i.e., recommendations that differ 
from normal population based screening practices through referrals, use of different technologies 
(e.g., breast MRI) or more intensive screening [e.g., starting colonoscopy at age 40 rather than 
50]) in R software [R Core Team, 2013]. We then searched each pedigree for the presence of 
each factor and verified that those with it, received the appropriate recommendation, and that 
those without, did not. This was done for every possible FHH risk factor-recommendation 
combination. The accuracy of the code was tested using multiple fictitious pedigrees designed to 
trigger recommendations. To assess the accuracy of MeTree's Gail Model and BRCAPRO 
calculations a random sample of 20 pedigrees with scores “above” and “below” the guideline 
recommended cut-offs were manually entered into the publicly available software programs and 
compared to scores generated by MeTree. 
To approximate the potential increase in resource demands created by applying risk stratification 
and risk-stratified guidelines to unselected primary care populations we evaluated the frequency 
of non-routine recommendations. Colonoscopy management of adenomatous polyps or 
inflammatory bowel disease is not considered non-routine in this paper since these practices are 
well entrenched in clinical practice and are routine disease management strategies. For each 
participant the number of non-routine recommendations was calculated and for each disease 
category the number and percent of participants given a non-routine recommendation were 
calculated. Non-routine recommendations were further subdivided into “hereditary syndrome 
risk” (received a genetic counseling (GC) recommendation) (indicating participants are at high 
risk for a hereditary cancer syndrome) and “familial-risk” recommendations (all non-routine 
recommendations except genetic counseling and genetic testing, indicating participants are above 
population-level risk but not at high risk for a hereditary cancer syndrome). We make this 
distinction because of the tremendous difference in absolute risk in the hereditary risk group 
versus the familial risk group, even though both are above population level risk. This is 
demonstrated by colon cancer risk in those with genetic mutations for Hereditary Non-Polyposis 
Colon Cancer (HNPCC) which are associated with a 40–80% lifetime risk of colon cancer (10-
fold higher than population risk), as compared to someone with a first degree relative that 
developed colon cancer at age ≥50, who has a 2- to 4-fold higher than population risk [Hendriks 
et al., 2006; Schoen et al., 2012]. In calculating percentages, patients with the disease under 
consideration were removed from the numerator and denominator. For example, participants 
with breast cancer were not included when calculating the percent of participants receiving a 
breast MRI recommendation for prevention. 
To better understand which FHH risk factors were driving the receipt of recommendations, we 
calculated the prevalence of each FHH risk factor and then tabulated according to frequency and 
type of recommendation (hereditary syndrome risk or familial-risk). To evaluate the relationship 
between patient characteristics and recommendations we performed Pearson's chi-square (two 
categorical variables), and analysis of variance F-test with Fisher's least significant difference 
(one categorical and one numeric variable). Age, ethnicity, family size, and percent of family 
with cancer were analyzed using a regression model to evaluate the relationship between them 
and the receipt of recommendations. Gender, which is significant due to the inclusion of female 
only cancers, was included only to obtain adjusted values for the other variables. Model selection 
was performed using a forward-backward stepwise approach that aims to minimize Akaike 
Information Criterion (AIC), a measure used to compare the relative quality of competing 
statistical models by maximizing goodness of fit for those with the fewest number of fitting 
parameters [Akaike, 1974]. Numeric outcomes were modeled using a standard linear regression, 
and categorical outcomes using logistic linear regression and bootstrapping was used to calculate 
the 95% confidence intervals for the mean proportion of affected relatives due to the highly 
skewed nature of the distributions. 
Lastly, to explore the differential impact of other existing, well-accepted guidelines we compared 
the frequency of recommendations generated when applying the National Comprehensive Cancer 
Network's (NCCN) guidelines for Colorectal Cancer Screening version 2.2012 and 
Genetic/Familial High-Risk Assessment: Breast and Ovarian version 1.2012 (available 
athttp://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp#detection), and the 
Michigan Department of Community Health's Cancer Family History Guide (available 
at http://www.michigan.gov/documents/mdch/PocketToolCard_344670_7.pdf) to the pedigrees 
collected by MeTree, using the same process as the one described for analytic validity. 
RESULTS 
Patient Characteristics 
The study population and a study flow diagram were previously published [Wu et al., 2013]. A 
total of 1,184 patients who were similar to the underlying clinic population except for slightly 
more women (58% vs. 42%) and fewer non-whites (20% vs. 25%) participated. A total of 27,406 
relatives were entered into MeTree (see Table II). The median number of relatives entered per 
pedigree was 21 (range 10–70), the median number of first degree relatives (FDRs) entered was 
5, and of second degree relatives (SDRs) was 15. For breast cancer 19% of participants had at 
least one affected FDR (2% had >1 affected FDR), and 21% had at least one affected SDR (5% 
had ≥2 affected SDRs, of which 4 had ≥4). Four male relatives were reported to have breast 
cancer. For colon cancer 11% of participants reported at least one affected FDR (1% had >1 
affected FDR) and 16% had at least one affected SDR (4% had >1 affected SDR, of which 2 had 
>3). There were 12 participants with at least one relative with Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC) and seven with at least one relative with Hereditary Non-Polyposis 
Colon Cancer (HNPCC). No participants reported relatives with Familial Adenomatous 
Polyposis (FAP), Li–Fraumeni Syndrome, or Cowden Syndrome. Table III lists the prevalence 
of CDS diseases by relative across all participants (e.g., average percent of relatives with breast 
cancer/pedigree for the study population) as well as for the subgroup of those with at least one 
relative with the disease under consideration (e.g., average percent of relatives with breast 
cancer/pedigree for only those participants with a FHH of breast cancer). The familial clustering 
of CDS diseases is evident by the high disease prevalence among the small proportion of 
families with at least one relative with the condition, while the predominance of families had no 
affected relatives. This is in opposition to the more even distribution that occurs when there is no 
clustering. 
Table II. Population Characteristics 
  Study patients (N = 1,184), N (%) 
Gender 
Male 490 (41.4) 
Female 694 (58.6) 
Ethnicity 
White 969 (81.8) 
Black 159 (13.5) 
Other 56 (4.7) 
Age 
Mean (SD) 58.8 (11.8) 
Education 
HS or less 158 (13.3) 
Some college 245 (20.7) 
College degree 461 (38.9) 
Gail score (SD) 0.0184 (0.01) 
No. of relatives (range) 22.89 (8–71) 
Disease prevalence (N (%)) 
Breast cancer (females only) 45 (6.5%) 
Colon cancer 5 (0.4%) 
Diabetes 110 (9.3%) 
Heart attacks 36 (3.0%) 
Thrombosis 53 (4.5%) 
Asthma 146 (12.9%) 
 a Adapted from table published in open access journal [Wu et 
al., 2013]. http://www.biomedcentral.com/1471-2296/14/111. 
 
Table III. Prevalence of Clinical Decision Support Conditions Among Participants' Relatives 
  All participantsa proportion 
of relatives affected mean 
(%) (CI) 
Participants with an 
affected 
relativeb number of 
participants N (%) 
Participants with an 
affected relativec 
proportion of 
relatives affected 
mean (%) (CI) 
Breast 
cancerd 
5% (4.7%, 5.6%) 441 (37%) 14% (12.9%, 14.5%) 
Ovarian 
cancerd 
1% (0.9%, 1.3%) 113 (10%) 11% (9.9%, 12.5%) 
Colon cancer 1% (1.3%, 1.7%) 279 (24%) 6% (5.92%, 6.76%) 
Hereditary 
cancer 
syndrome 
0% (0.1%, 0.3%) 29 (2%) 8.7% (6.7%, 10.9%) 
Thrombosis 2% (1.6%, 2.0%) 324 (27%) 7% (6.1%, 7.0%) 
a Values reported in the column represent the percent of relatives within each participant's 
pedigree that have the specific condition—averaged across all participants (N = 1,184). 
b Values reported in the column represent the number of participants who had at least one relative 
with the specific condition. This subset represent the pedigrees averaged in the column to the 
right. 
c Values reported in the column represent the percent of relatives within each participant's 
pedigree that have the specific condition—averaged across the participants with an affected 
relative (column to the left). 
d The mean percent of affected relatives is calculated using only female relatives as the 
denominator for these two conditions. 
 
Analytic Validity 
MeTree appropriately generated recommendations for all participants based upon the FHH risk 
factors specified in the guidelines and accurately calculated BRCAPRO [Berry et al., 2002] and 
Gail Model [Gail et al., 1989] risk scores in the 20 validation cases. 
Recommendations 
There were 761 non-routine recommendations generated on 44% of participants (523/1,184). Of 
the 761 recommendations 55% (416/761) were for “hereditary syndrome risk” (genetic 
counseling recommendation). Among participants receiving a non-routine recommendation 63% 
(330/523) received a genetic counseling recommendation (22 related to thrombosis, 301 to 
cancer, 7 to both), and 59% (307/523) received a “familial-risk” recommendation. This includes 
176 participants who received more than one recommendation (128 with 2 recommendations and 
48 with more than 2). Of the 128 with 2 recommendations, 17 received 2 GC recommendations, 
76 received 1 GC and 1 “familial-risk” recommendation, and 35 received 2 “familial-risk” 
recommendations. Of the 48 with >2 recommendations, 8 received all GC recommendations, 2 
received all “familial-risk” recommendations, and the remaining 38 received some combination 
of GC and “familial-risk” recommendations. When considering resource impact, 330 (28.4%) 
needed referral to a GC, 14 (1.2%) a referral to gynecology, 221 (18.6%) more intensive colon 
cancer screening, and 10 (0.8%) breast MRI. Table IV lists the number and percent of 
participants receiving “hereditary syndrome risk” and “familial-risk” recommendations across 
the full study population and within the subgroup of participants eligible for the recommendation 
(e.g., removing men from the denominator of ovarian cancer recommendations). 
Table IV. Frequency of Hereditary Syndrome Risk and Familial-Risk Recommendations for 
Each Clinical Decision Support Condition 
Disease Recommendation Frequency among all 
participants (N = 1,184), 
N (%) 
Frequency among 
eligible participantsa, N 
(%) 
Hereditary 
syndrome risk 
Genetic counselingb 308 (26.0%) 308/1,184 (26.0%) 
Breast cancer Breast MRI 10 (0.8%) 10/694 (1.4%) 
  Chemoprophylaxis 58 (4.9%) 58/694 (8.3%) 
Colon cancer Start colon screening 
early 
114 (9.6%) 114/1,178 (9.7%) 
  More frequent 
colonoscopies 
107 (9.0%) 107/1,178 (9.1%) 
Ovarian cancer Referral to 
gynecology 
14 (1.2%) 14/694 (2.0%) 
Thrombosis Genetic testingb 42 (3.5%) 42/1,184 (3.5%) 
  Genetic counselingb 29 (2.4%) 29/1,184 (2.4%) 
a The number of participants eligible for a recommendation in that disease category. Those with 
the disease are removed and for breast cancer and ovarian cancer, men are removed. 
b These recommendations make up the “hereditary syndrome risk” group, the others up the 
“familial-risk” group. 
 
Prevalence of FHH Risk Factors 
To better understand which FHH risk factors were driving the receipt of non-routine 
recommendations, we calculated the prevalence of each and categorized according to type of 
recommendation: “hereditary syndrome risk” (genetic counseling referral) or “familial-risk.” 
Data are presented as the number of individuals with the risk factor and its prevalence in the 
population (N/1,184). Among “hereditary risk” recommendations (N = 416) the most common 
FHH risk factors were: (1) three or more relatives with HNPCC related cancers (N = 65, 5.4%); 
(2) three or more relatives on the same side of the family with the same cancer (N = 59, 4.9%); 
(3) two or more relatives with breast cancer, at least one with an age of onset at or before 50 
years (N = 49, 4.1%); and (4) at least one relative with breast cancer at or before 40 years 
(N = 48, 4.1%). Among “familial-risk” recommendations (N = 345) the most frequent FHH risk 
factors are: (1) an FDR with colon polyps diagnosed at or after age 60 (N = 85, 7.1%) (start 
colorectal cancer surveillance at age 40); (2) an FDR with colon polyps diagnosed before age 60 
(N = 61, 5.1%) (start colonoscopies at age 40 or 10 years prior to relative's age at diagnosis and 
perform every 5 years); (3) a 5-year Gail score ≥1.66% (N = 58, 4.9%) (consider breast cancer 
chemoprevention); and (4) an FDR with colon cancer diagnosed at or after age 60 (N = 20, 1.7%) 
(start colorectal cancer surveillance at age 40). 
Factors Related to Receiving Non-Routine Recommendations 
In multivariate analysis the likelihood of receiving any non-routine MeTree recommendation 
was only significant for mean family size (24.5 for yes recommendation vs. 21.6 for 
no, P = 4e−8) and mean percent of family with cancer (17.3 for yes vs. 10.9 for no, P = 2e−26), 
while the likelihood of receiving a genetic counseling recommendation was significantly higher 
for individuals with older age (58.3 for no GC vs. 59.9 for yes, P = 0.03), larger mean family size 
(22.2 for no vs. 24.7 for yes, P = 8e−6), and mean percent of family with cancer (11.2 for no vs. 
20.3 for yes, P = 6e−44). These findings are not surprising given the dependence of 
recommendations upon the presence of disease within families. This same trend was also present 
across disease specific recommendations such as breast MRI. 
Comparison to Other Sources 
To explore the differential impact of other well-accepted guidelines and screening tools on non-
routine recommendation frequency, and thus resource needs, we compared MeTree genetic 
counseling recommendations (for breast, ovarian, and colon cancer) to those that would have 
been generated if (1) the National Comprehensive Cancer Network (NCCN) Guidelines for 
breast/ovarian and colorectal cancer screening and (2) the Michigan Department of Community 
Health's Cancer Family History Guide (CFHG) were applied to the same population. 
Table V reports the frequency of genetic counseling recommendations for each and where they 
agreed and disagreed. 
Table V. Comparison of Genetic Counseling (GC) Referral Recommendations Between MeTree, 
and the NCCN's Colon and Breast Cancer Guidelines, and the Michigan Department of 
Community Health's Cancer Family History Guide (CFHG) 
  MeTree GC referral Total 
No, N (%) Yes, N (%) 
CFHG GC referral 
No 768 (64.9%) 94 (7.9%) 862 (72.8%) 
Yes 86 (7.3%) 236 (19.9%) 322 (27.2%) 
Total 854 (72.1%) 330 (27.9%) 1,184 (100%) 
NCCN breast cancer GC referral 
No 891 (75.3%) 12 (1.0%) 903 (76.2%) 
Yes 114 (9.6%) 167 (14.1%) 281 (23.7%) 
Total 1,005 (84.9%) 179 (15.1%) 1,184 (100%) 
NCCN colon cancer GC referral 
No 1,070 (90.4%) 103 (8.7%) 1,173 (99.1%) 
Yes 0 (0%) 11 (0.9%) 11 (0.9%) 
Total 1,070 (90.4%) 114 (9.6%) 1,184 (100%) 
 
The total number of MeTree and CFHG genetic counseling recommendations was similar (330 
vs. 322) and agreement was 85% (agreed to refer + agreed not to refer) with a κ = 0.619. When 
comparing MeTree to the NCCN hereditary breast/ovarian cancer guidelines, genetic counseling 
was recommended less frequently by MeTree (179 vs. 281); agreement was 89% with a 
κ = 0.664. Most of the difference was due to NCCN referring for either any relative with ovarian 
cancer (N = 66, 65%), or for a family member with breast cancer onset at or before age 45 
(MeTree uses a cut-off of 40) (N = 32, 32%). This pattern was reversed when looking at the 
NCCN hereditary colon cancer guidelines with MeTree recommending genetic counseling for 
114 and NCCN for only 11; agreement was 90% with a κ = 0.162. This difference was entirely 
due to MeTree's inclusion of stomach, ovarian, pancreatic, and brain cancers (Bethesda Criteria) 
as a risk factor for HNPCC, while NCCN included them as a risk factor only for individuals with 
colon cancer themselves or an FDR or SDR with colon cancer [Umar et al., 2004]. 
DISCUSSION 
Risk stratification and risk-stratified preventive guidelines are a critical component of 
incorporating genomic and personalized medicine into primary care and are important tools for 
improving both the quality and the cost-effectiveness of medical care. 
Risk stratification and risk-stratified preventive guidelines are a critical component of 
incorporating genomic and personalized medicine into primary care and are important tools for 
improving both the quality and the cost-effectiveness of medical care. 
When interventions are targeted to risk level, the balance of risk and benefits shift towards 
applying the right “treatment” to the right patient at the right time [Grimes et al., 2012]. 
However, risk stratification is time intensive and requires the collection of high quality FHH and 
personal data that is often not feasible in the context of a routine primary care visit [NIH, 2009]. 
Risk stratification and clinical decision support tools, like MeTree, Family Healthware™ [Yoon 
et al., 2009], Health Heritage© [Cohn et al., 2010], Hughes riskApps™ [Ozanne et al., 2009], and 
others are designed to overcome these obstacles. In this paper we show that when implementing 
MeTree in an unselected primary care population, 44% of patients meet criteria for non-routine 
risk-management/prevention strategies for breast/ovarian cancer, colon cancer, hereditary cancer 
syndrome risk, and thrombosis and that many of the recommendations clustered within 
participants (176/523 received more than 1 recommendation)—not surprising given the familial 
clustering of conditions upon which recommendations were based (Table III). This supports the 
notion that MeTree is able to capture high-risk individuals and appropriately target preventive 
resources. 
The high frequency of non-routine recommendations may mean that successful implementation 
will result in an unanticipated demand for recommended resources; largely genetic counseling 
(26% of study population) and colon cancer screening modalities (18.6% of study population) 
(Table IV). Genetic counseling is an already limited commodity and few PCPs have an 
established relationship with a genetic counselor or medical geneticist. While increased training 
in these fields will help, broader adoption of alternative counseling modalities such as 
telegenetics and phone counseling can expand access and help to accommodate increases in 
demand [Hemminki et al., 2008; Neale et al., 2013]. For colon cancer screening, PCPs and 
gastroenterologists may end up sharing the additional workload, depending upon screening 
modality (in some recommendations colonoscopy is required, but in others any screening 
modality is acceptable). For example, if in an increased surveillance recommendation, choice of 
modality is optional (such as when an FDR is diagnosed with polyps at or after age 60), and 
providers opt for fecal occult blood cards, management would fall to the PCP; alternatively, if 
colonoscopy is chosen as the modality or specified by the recommendation, increased demand 
would fall upon gastroenterologists possibly creating a need for more gastroenterologists or for 
existing gastroenterologists to spend more time performing colonoscopies. Altogether, this 
suggests that the feasibility of adopting risk-stratification should take into consideration the 
expected frequency of non-routine recommendations derived from risk-stratification and the 
potential for higher demand for limited resources. 
One way to predict the frequency of non-routine recommendations is to know the prevalence of 
FHH risk factors in the underlying population. Understanding prevalence would allow policy 
makers to project resource needs and could guide decision making prior to implementation. In 
our study, many of the recommendations were due to the high prevalence of a few FHH risk 
factors. Eight were responsible for 18.5% of genetic counseling and 18.8% of familial-risk 
recommendations—in total 37.3% of all recommendations. The remainder was responsible for 
<3% each. Thus even without monitoring all FHH risk factors, awareness of prevalence can help 
identify selected factors to monitor when estimating changes in resource availability. 
The effect that prevalence can have on a population is demonstrated by the difference in 
MeTree's and NCCN's genetic counseling recommendations for HNPCC risk. Both incorporate 
the Bethesda criteria in their risk assessment; but in the case of NCCN it was only included when 
the participant or his/her close relative had colon cancer; therefore, the prevalence of colon 
cancer limited the application of the Bethesda criteria. This one difference resulted in 10-fold 
fewer referral recommendations by NCCN (N = 11) than by MeTree (the same 11 plus 103 
more). Even when the overall recommendation numbers seem almost identical, such as in the 
comparison of MeTree (N = 330) to the Cancer Family History Guide (N = 322), differences at 
the individual level are present. In this case only 236 were referred by both, the other one-third 
were referred by one but not the other and vice versa. Though the relatively high agreement 
seems counterintuitive when focusing upon the differences in genetic counseling referral 
recommendations, the agreement values and the Kappas reflect the high frequency with which 
the guidelines agreed not to refer the majority of participants. The lower Kappa for NCCN colon 
cancer is due to the very low number of “non-routine” recommendations compared to routine, 
rather than a high disagreement rate. Extrapolating, low prevalence leads to a low impact on the 
overall population, but still may profoundly affect individuals (identifying small numbers of 
individuals who would otherwise not have been found to be at high risk); but high prevalence 
leads to a high impact on both populations and individuals. 
These data highlight the importance of understanding FHH risk factors, their prevalence, and 
their relationship to outcomes in order to inform guideline development. However, in contrast to 
sensitivity and specificity for which data exists, surprisingly little is known about prevalence in 
the general population and what is published references selected populations, typically probands 
affected by a disease of interest [Hemminki et al., 2008; Grimes et al., 2012; Neale et al., 2013]. 
In addition, guideline development teams rarely, if ever, consider the downstream consequences 
of implementation. Once prevalence and population impact is clearly understood including 
downstream impact on resource use should also be considered. One way to create this 
knowledge-base is to develop and maintain a high quality FHH database comprised of unselected 
representative U.S. individuals. This effort could be similar to those currently underway for 
genetic sequencing [Genomes Project et al., 2012]. 
Limitations of our study are several. First, MeTree's analytic validity could have been poor and 
thus not appropriately represent the risk-stratified guidelines. While it had undergone several 
phases of assessment, including a review of all pedigrees and recommendations by a genetic 
counselor during the first 6 months of the clinical trial [Orlando et al., 2013a], we wanted to 
systematically assess the programming structure using the entire study population. The results 
suggest that MeTree is accurate and that widespread adoption of the guidelines upon which it is 
based would result in a similar frequency of non-routine recommendations (given differences in 
the underlying populations). Second, the patient population in our study may not have been 
representative of primary care populations in general or even of the clinics from which they were 
recruited. In particular it is possible that primary care patients with a strong FHH of cancer 
would be more aware of their risk or more aware of the diseases present in their family and thus 
more likely to participate in the study, which would skew the frequency of non-routine 
recommendations upward. Three points argue against this: participants were demographically 
quite similar to the clinic population, relative-type recurrence-risk ratios from our population are 
similar to those reported in other unselected populations (data not reported here but is in review) 
[Risch, 1990], and the percent of participants identified as at increased risk is consistent with that 
reported by other primary care based risk-stratification tools, 42–82% depending upon the 
number of conditions considered and the criteria for assigning risk (FHH risk factors) [O'Neill et 
al., 2009; Cohn et al., 2010; Rubinstein et al., 2011]. When considering only conditions 
represented in MeTree's CDS, the Family Healthware Trial categorized 42% as higher than 
population risk, almost identical to MeTree's 44% [O'Neill et al., 2009]. A third limitation is the 
dependence of MeTree (and any other tool with the goal to improve uptake of guidelines) upon 
the validity of the guidelines. As shown in this paper, small differences in guideline criteria 
result in big differences in population impact, and many are based on consensus. Making sure 
that the guidelines are better informed through better data is one of the main objectives of this 
paper which serves as a call to create more data driven guidelines. In addition, guidelines change 
and keeping tools, like MeTree updated are critical to their functionality. In our case, we have a 
team dedicated to updating the algorithms as guidelines change. See the referenced paper for 
more details on this process [Orlando et al., 2013a]. Finally, the fourth limitation is that in the 
resource demands discussion we assumed providers and patients would adhere to the CDS 
recommendations. Since there may be many reasons why participants should not undergo the 
recommended action, adherence will never be complete. Future research exploring factors 
affecting adherence to the recommendations will help to improve the accuracy of projections. 
Taken together these suggest that (1) MeTree performs appropriately and its result are 
representative of what might be found when implementing risk-stratification in primary care, and 
(2) given the few conditions represented in MeTree's clinical decision support, broadening risk 
stratification to incorporate all evidence-based risk-stratified action-oriented risk-
management/prevention guidelines would lead to considerably more non-routine 
recommendations. 
In conclusion, MeTree can successfully integrate guideline risk stratification and management 
into the care of primary care populations but that in the process we should anticipate an increase 
in demand for certain resources, particularly genetic counseling. Developing a database of 
personal and FHH is one way to anticipate these demands and help prepare for them as well as to 
inform guideline development. 
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